# US 2021/0061894 A1 · Immunological Targeting of Pathological Tau Proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061894 A1
- Document ID: US20210061894A1
- Status: Published application
- Kind: A1
- Application number: 17/090,359
- Filed: 2020-11-05
- Published: 2021-03-04
- Earliest claimed: 2009-06-10
- Assignees: New York University
- Applicants: New York University
- Inventors: Einar M. Sigurdsson
- Web page: https://patentgrep.com/patent/US20210061894A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/2821: Alzheimer
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.

## Claims

### Claim 1

A method of treating Alzheimer's disease or other tauopathy in a subject, or of reducing the severity of Alzheimer's disease or said other tauopathy in said subject, said method comprising:
administering to said subject an immunogenic tau peptide (I) whose amino acid sequence consists of the amino acid sequence of:
(a)
SEQ ID NO: 3
IGS*TE (Tau260-264 P-Ser262);
or
SEQ ID NO: 32
IGX TE (Tau260-264 Pseudo P-Ser262);
(b)
SEQ ID NO: 12
IGS*TENLKHQPG (Tau260-271 P-Ser262);
or
SEQ ID NO: 41
IGX TENLKHQPG (Tau260-271 Pseudo P-Ser262);
(c)
SEQ ID NO: 20
VKS*KIGS*TE (Tau256-264 P-Ser262);
or
SEQ ID NO: 49
VKX KIGX TE (Tau256-264 Pseudo P-Ser262);
or
(d)
SEQ ID NO: 94
KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
(Tau240-270 P-Ser262);
or
SEQ ID NO: 69
KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
(Tau240-270 Pseudo P-Ser262);
wherein:
S* and P-Ser denote a phospho-serine residue, and X and Pseudo P-Ser denote a glutamic acid or aspartic acid residue;
said immunogenic tau peptide (I) peptide is administered in an amount sufficient to elicit an active immune response in said subject to said immunogenic tau peptide; and
said elicited active immune response provides said subject with treatment of Alzheimer's disease or said other tauopathy or reduces the severity of Alzheimer's disease or said other tauopathy in said subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said immunogenic tau peptide (I) is linked to an immunogenic carrier.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said immunogenic tau peptide (I) is said peptide whose amino acid sequence consists of the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:32.

### Claim 4 (depends on 2)

The method according to claim 2, wherein said immunogenic tau peptide (I) is said peptide whose amino acid sequence consists of the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:41.

### Claim 5 (depends on 2)

The method according to claim 2, wherein said immunogenic tau peptide (I) is said peptide whose amino acid sequence consists of the amino acid sequence of SEQ ID NO:20 or SEQ ID NO:49.

### Claim 6 (depends on 2)

The method according to claim 2, wherein said immunogenic tau peptide (I) is said peptide whose amino acid sequence consists of the amino acid sequence of SEQ ID NO:94 or SEQ ID NO:69.

### Claim 7 (depends on 2)

The method according to claim 2, wherein an adjuvant is administered before, after, or concurrent with said administration of said immunogenic tau peptide (I).

### Claim 8 (depends on 2)

The method according to claim 2, wherein said method comprises the administration of said immunogenic tau peptide (I), and one or more additional immunogenic tau peptides before, after, or concurrent with said administration of said immunogenic tau peptide (I); wherein each of said additional administered tau peptides has an amino acid sequence selected from the group consisting of SEQ ID NOs:81-100.

### Claim 9 (depends on 2)

The method according to claim 2, wherein said immunogenic carrier is keyhole limpet hemocyanin (KLH).

### Claim 10 (depends on 1)

The method according to claim 1, wherein said tauopathy is selected from the group consisting of frontotemporal dementia, parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, progressive subcortical gliosis, tangle only dementia, diffuse neurofibrillary tangles with calcification, argyrophilic grain dementia, amyotrophic lateral sclerosis parkinsonism-dementia complex, dementia pugilistica, Down syndrome, Gerstmann-Straussler-Scheinker disease, Hallerworden-Spatz disease, inclusion body myositis, Creutzfeld-Jakob disease, multiple system atrophy, Niemann-Pick disease type C, prion protein cerebral amyloid angiopathy, subacute sclerosing panencephalitis, myotonic dystrophy, non-guanamian motor neuron disease with neurofibrillary tangles, chronic traumatic encephalopathy, and postencephalitic parkinsonism.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said method promotes reduction or clearance of tau aggregates from the brain of said subject, or reduces the severity of the formation of tau aggregates in said subject.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said aggregates are neurofibrillary tangles or their pathological tau precursors.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said method slows progression of a tau-pathology related cognitive impairment in said subject, or reduces the severity or duration of said progression in said subject.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said wherein said elicited active immune response provides said subject with treatment of Alzheimer's disease or said other tauopathy or reduces the severity of Alzheimer's disease or said other tauopathy in said subject.

### Claim 15

A pharmaceutical composition comprising:
(A) an immunogenic tau peptide (I) whose amino acid sequence consists of the amino acid sequence of:
(a)
SEQ ID NO: 3
IGS*TE (Tau260-264 P-Ser262);
or
SEQ ID NO: 32
IGX TE (Tau260-264 Pseudo P-Ser262);
(b)
SEQ ID NO: 12
IGS*TENLKHQPG (Tau260-271 P-Ser262);
or
SEQ ID NO: 41
IGX TENLKHQPG (Tau260-271 Pseudo P-Ser262);
(c)
SEQ ID NO: 20
VKS*KIGS*TE (Tau256-264 P-Ser262);
or
SEQ ID NO: 49
VKX KIGX TE (Tau256-264 Pseudo P-Ser262);
or
(d)
SEQ ID NO: 94
KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
(Tau240-270 P-Ser262);
or
SEQ ID NO: 69
KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
(Tau240-270 Pseudo P-Ser262);
wherein:
S* and P-Ser denote a phospho-serine residue, and X and Pseudo P-Ser denote a glutamic acid or aspartic acid residue;
(B) a pharmaceutically-acceptable carrier, diluent or stabilizer;
wherein said composition comprises an amount of said immunogenic tau peptide (I) sufficient to treat Alzheimer's disease or other tauopathy in a recipient subject or to reduce the severity of Alzheimer's disease or said other tauopathy in said recipient subject.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein said immunogenic tau peptide (I) is linked to an immunogenic carrier.

### Claim 17 (depends on 15)

The pharmaceutical composition according to claim 15, wherein said tauopathy is selected from the group consisting of frontotemporal dementia, parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, progressive subcortical gliosis, tangle only dementia, diffuse neurofibrillary tangles with calcification, argyrophilic grain dementia, amyotrophic lateral sclerosis parkinsonism-dementia complex, dementia pugilistica, Down syndrome, Gerstmann-Straussler-Scheinker disease, Hallerworden-Spatz disease, inclusion body myositis, Creutzfeld-Jakob disease, multiple system atrophy, Niemann-Pick disease type C, prion protein cerebral amyloid angiopathy, subacute sclerosing panencephalitis, myotonic dystrophy, non-guanamian motor neuron disease with neurofibrillary tangles, chronic traumatic encephalopathy, and postencephalitic parkinsonism.

### Claim 18 (depends on 15)

The pharmaceutical composition according to claim 15, wherein administration of said immunogenic tau peptide (I) to a subject promotes reduction or clearance of tau aggregates from the brain of said subject, or reduces the severity of the formation of tau aggregates in said subject.

### Claim 19 (depends on 15)

The pharmaceutical composition according to claim 15, wherein administration of said immunogenic tau peptide (I) to a subject slows progression of a tau-pathology related cognitive impairment in said subject, or reduces the severity or duration of said progression in said subject.

### Claim 20 (depends on 15)

The pharmaceutical composition according to claim 15, wherein administration of said immunogenic tau peptide (I) to a subject provides said subject with treatment of Alzheimer's disease or said other tauopathy or reduces the severity of Alzheimer's disease or said other tauopathy in said subject.
